Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Interest Expenses (2025)

Soleno Therapeutics (SLNO) has disclosed Interest Expenses for 4 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses changed N/A to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $5.5 million for FY2025, 2270.56% up from the prior year.
  • Interest Expenses for Q4 2025 was $1.3 million at Soleno Therapeutics, down from $1.4 million in the prior quarter.
  • The five-year high for Interest Expenses was $1.4 million in Q3 2025, with the low at $1.3 million in Q4 2025.